Ultragenyx Pharmaceutical Inc [RARE] Insider Activity: An Update for Investors

Ultragenyx Pharmaceutical Inc’s recent filing unveils that its Director Sanders Corazon (Corsee) D. unloaded Company’s shares for reported $89923.0 on Jun 20 ’25. In the deal valued at $37.39 per share,2,405 shares were sold. As a result of this transaction, Sanders Corazon (Corsee) D. now holds 15,344 shares worth roughly $0.61 million.

Then, CORAZON D. SANDERS bought 2,405 shares, generating $89,923 in total proceeds.

Before that, Crombez Eric sold 520 shares. Ultragenyx Pharmaceutical Inc shares valued at $20,405 were divested by the EVP and Chief Medical Officer at a price of $39.24 per share. As a result of the transaction, Crombez Eric now holds 71,530 shares, worth roughly $2.83 million.

William Blair initiated its Ultragenyx Pharmaceutical Inc [RARE] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in early June from “a Neutral” to “a Buy”. RBC Capital Mkts began covering RARE with “an Outperform” recommendation on April 22, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated RARE as “an Overweight”.

Price Performance Review of RARE

On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock fall -0.75% to $39.61. Over the last five days, the stock has gained 8.46%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -3.30% since the year began. Nevertheless, the stocks have fallen -5.85% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $29.59 was recorded on 04/09/25.

Levels Of Support And Resistance For RARE Stock

The 24-hour chart illustrates a support level at 39.08, which if violated will result in even more drops to 38.55. On the upside, there is a resistance level at 39.97. A further resistance level may holdings at 40.32.

How much short interest is there in Ultragenyx Pharmaceutical Inc?

A steep rise in short interest was recorded in Ultragenyx Pharmaceutical Inc stocks on 2025-06-13, growing by 0.19 million shares to a total of 6.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.89 million shares. There was a rise of 3.11%, which implies that there is a positive sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.